Shopping Cart
- Remove All
- Your shopping cart is currently empty
SIJ1777, a derivative of GNF-7, exhibits potent anticancer effects against melanoma cells harboring BRAFI/II/III mutations. The compound significantly inhibits the activation of MEK, ERK, and AKT. Furthermore, SIJ1777 notably induces apoptosis (cell death) and effectively prevents migration, invasion, and anchorage-independent growth of melanoma cells with BRAFI/II/III mutations.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | SIJ1777, a derivative of GNF-7, exhibits potent anticancer effects against melanoma cells harboring BRAFI/II/III mutations. The compound significantly inhibits the activation of MEK, ERK, and AKT. Furthermore, SIJ1777 notably induces apoptosis (cell death) and effectively prevents migration, invasion, and anchorage-independent growth of melanoma cells with BRAFI/II/III mutations. |
In vitro | SIJ1777 exhibits enhanced antiproliferative activity against melanoma cells (SK-MEL-2, SK-MEL-28, A375, WM3670, WM3629) compared to GNF-7, with a 2 to 14-fold increase. This enhancement is observed irrespective of the BRAF mutation status in the melanoma cells, where SIJ1777 completely inhibits the phosphorylation levels of MEK, -ERK, and -AKT at a concentration of 1 μM. Additionally, SIJ1777 increases the levels of cleaved PARP in a concentration-dependent manner in melanoma cells (SK-MEL-2, SK-MEL-28, C8161, WM3629). |
Molecular Weight | 536.51 |
Formula | C26H23F3N8O2 |
Cas No. | 839707-55-0 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.